Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taribavirin
- Development stage
- Phase 3
- Lead developer
- Valeant Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Taribavirin is an investigational antiviral drug and a prodrug of ribavirin. It is designed to be converted into ribavirin in the body and was developed to treat hepatitis C virus (HCV) infection with the aim of reducing the risk of hemolytic anemia associated with ribavirin therapy. Taribavirin acts as a nucleoside analogue that inhibits viral RNA synthesis by targeting viral RNA-dependent RNA polymerase after conversion to its active form. The drug was primarily developed by Valeant Pharmaceuticals for use in combination with interferon-based therapies for chronic hepatitis C.
- Other names
- taribavirinviramidineICN-3142ICN3142ICN 3142
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on taribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taribavirin.